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MOLECULAR CHARACTERIZATION OF VANCOMYCIN-RESISTANT Enterococci STRAINS EIGHT
YEARS APART FROM ITS FIRST ISOLATION IN SÃO PAULO, BRAZIL
Pedro Alves D’AZEVEDO(1,2), Guilherme H.C. FURTADO(3), Eduardo A.S. MEDEIROS(3), Kelly Aline SANTIAGO(1), Suzane SILBERT(1) & Antonio C.C. PIGNATARI(1)
SUMMARY
E. faecium was the first reported VRE species, carrying the vanA gene in Brazil. In spite of this, vancomycin-resistant E.
faecalis has become the predominant species in Brazilian hospitals. The aim of this study was to evaluate the genetic relatedness
of VREs isolated in a Brazilian teaching hospital eight years apart from its first isolation. We analyzed 38 VRE strains obtained
from 81 surveillance cultures of patients admitted to the four largest intensive care units in Hospital São Paulo in February, 2006.
Presence of the vanA gene was assayed by PCR and PFGE analysis was used for molecular characterization. All VRE strains
carried the vanA gene. Two distinct clonal groups were observed among vancomycin-resistant E. faecalis. Vancomycin-resistant
E. faecium belonged to five distinct clones were demonstrated by molecular typing. All of these clones were different from the first
vancomycin-resistant enterococci clone isolated eight years ago in our hospital.
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INTRODUCTION
Enterococci became an important nosocomial pathogen due to their
increasing role as opportunistic agents and their special ability to
acquire resistance to antimicrobial drugs, including vancomycin18.
Vancomycin-resistant enterococci (VRE) are a common cause of
nosocomial infections and are important agents of gastrointestinal
colonization. As the prevalence of VRE in hospitalized patients
continues to increase, implementation of appropriate infection control
measures requires routine surveillance of VRE transmission patterns19.
The first cases of human infections associated with VRE were
detected in the late 1980s in Europe16 and in the United States15. Since
then, VRE isolation has been reported from different parts of the world4
and surveillance programs for early VRE detection are currently
recommended in order to prevent VRE spreading19. Vancomycin-
resistant enterococci have been an emerging problem in some Brazilian
hospitals since the late 1990s. The first report of a VRE infection in
Brazil occurred in 1996, in Curitiba10. Since 1997, the occurrence of
VRE outbreaks has been documented in hospitals from other Brazilian
cities1,8,9,12,13,22,25,26. Vancomycin-resistant enterococci have been isolated
in Hospital São Paulo (HSP) since 1998. Since then, a surveillance
program has been carried out by the Infection Control Committee in
order to identify patients harboring VRE and to implement contact
precautions. Despite this intervention, vancomycin-resistant
Enterococcus faecalis has became endemic in our setting thereafter.
On the other hand, studies on the clonality of vancomycin-resistant
enterococci (VRE) are still limited in Brazil, mainly due to territory
dimension, the differences in the population characteristics, and the
number of nosocomial institutions over the country. The aim of this
study was to determine the phenotypic and genotypic characteristics
of VRE isolates eight years apart from its first isolation in our setting.
MATERIALS AND METHODS
Hospital São Paulo is a 750-bed university-affiliated hospital with
an average of 177,000 patient-days per year. It comprises nine intensive
care units (ICUs) and 41 medical and surgical wards. Since 1998, the
Infection Control Committee has recorded the VRE incidence rate
throughout the hospital. Surveillance through active rectal swab has
been performed weekly in the four ICUs (Medical-Surgical, Medical,
Pneumonology and Emergency) that have maintained higher rates of
VRE incidence in the hospital. This incidence has varied from 17.4
isolates per 1,000 patient-days at Medical-Surgical ICU to 50.3 isolates
per 1,000 patient-days at Emergency ICU. A total of 81 rectal swabs
(one for each patient) obtained from patients admitted to those ICUs
in February 2006 were examined. Only patients admitted for more
than 48 hours were eligible for the study. All the rectal swabs were
collected by the infection control team. Fecal samples were inoculated
onto NaCl 0.9% and, after one hour, they were cultivated in VREBAC
medium (PROBAC, Brazil) and incubated at 35 °C for 18-24 hours.
Suspected VRE colonies were submitted to identification using
conventional biochemical tests and antimicrobial susceptibility11.
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Susceptibility to five antimicrobials (ampicillin, high-level gentamicin,
high-level streptomycin, teicoplanin, and vancomycin) was evaluated
by disk diffusion test, according to the Clinical Laboratory Standards
Institute (CLSI)7. Minimum inhibitory concentrations (MICs) of
ampicillin, gentamicin, streptomycin, teicoplanin and vancomycin were
also determined by the gradient diffusion test (E test; AB Biodisk,
Solna, Sweden) and by the agar-dilution method according to the CLSI
guidelines7, in those isolates that presented resistance.
Detection of vancomycin-resistance genes was performed by
polymerase chain reaction (PCR), using methods previously described6.
The genetic relatedness of bacterial strains was evaluated by PFGE.
Briefly, bacterial DNA was digested with SmaI and the restriction
fragments were separated by electrophoresis on the CHEF DR III
apparatus (BioRad, Hercules, CA). Running parameters were as follows:
200 V (6 V/cm); temperature, 13 °C; initial switch time 5’ and final 60’
for 23h. After the electrophoresis run was completed, the PFGE gel was
stained in a 0.08 µg/mL ethidium bromide solution. Macrorestriction
patterns were determined by visual inspection. The isolates were
classified as identical if they shared the same band profile, and different
when differing by seven or more bands23. Three reference VRE strains
were used to compare profiles in this study (first E. faecalis from HSP,
first E. faecium from HSP and first E. faecalis from Porto Alegre).
RESULTS
Vancomycin-resistant isolates were detected in 37 (45.7%) out of
81 fecal cultures. Vancomycin-resistant E. faecium was detected in 20
(54.1%) out of these 37 patients and vancomycin-resistant. E. faecalis
in 17 (45.9%) out of these 37 patients. The proportion of colonized
patients in ICUs was: Pneumonology - 41.6%; Medical-Surgical - 14.2%;
Emergency - 15.3% and Medical - 40%. Two different VRE species
were detected in one patient (E. faecalis and E. faecium). The species
isolates were identified and had their antimicrobial susceptibilities
determined. The strains presented MICs of 1024 µg/mL and 256 µg/mL
for vancomycin and teicoplanin respectively, and they all harbored the
vanA gene. The MICs for gentamicin and streptomycin in E. faecalis
were variable. 41.2% (7/17) and 29.4% (5/17) were gentamicin-resistant
and streptomycin-resistant respectively. In E. faecium, gentamicin
resistance and streptomycin-resistance were 15.0% (3/20) and 90.0%
(18/20), respectively. None E. faecalis strain was resistant to ampicillin
whereas 95.0% (19/20) of E. faecium strains were ampicillin-resistant.
With regard to the phenotypic similarity of species isolates, only two
isolates per intensive care unit were randomly selected to be analyzed
by PFGE (Tables 1 and 2). PFGE revealed the presence of two distinct
vancomycin-resistant E. faecalis clones (Fig. 1) and five distinct E.
faecium clones (Fig. 2). Among E. faecium, one of these clones were
Table 1
Results of nine vancomycin-resistant E. faecalis typed by PFGE
Number DD AMP/VANCO1 E-test vancomycin/teicoplanin µg/mL ICU2 Profile of PFGE
1 S/R 1024/256 Medical-surgical “A”
2 S/R 1024/256 Medical-surgical “A”
3 S/R 1024/256 Medical-surgical “B”
4 S/R 1024/256 Emergency “B”
5 S/R 1024/256 Emergency “B”
6 S/R 1024/256 Emergency “B”
7 S/R 1024/256 Medical “B”
8 S/R 1024/256 Medical “B”
9 R/R 1024/256 First E. faecalis from HSP “C”
1DD AMP/VANCO: disc diffusion test for ampicillin (10 µg) and vancomycin (30 µg); S: susceptible; R: resistant; 2intensive care units.
Table 2
Results of ten vancomycin-resistant E. faecium typed by PFGE
Number DD AMP/VANCO1 E-test vancomycin/teicoplanin µg/mL ICU2 Profile of PFGE
1 R/R 1024/256 Pneumonology “A”
2 S/R 1024/256 Medical-surgical “B”
3 R/R 1024/256 Medical-surgical “C1”
4 R/R 1024/256 Medical-surgical “D”
5 R/R 1024/256 Emergency “C2”
6 R/R 1024/256 Medical “B”
7 R/R 1024/256 Pneumonology “B”
8 R/R 1024/256 Emergency “B”
9 R/R 1024/256 Medical “E”
10 R/R 1024/256 First E. faecium from HSP “F”
1DD AMP/VANCO: disc diffusion test for ampicillin (10 µg) and vancomycin (30 µg); S: susceptible; R: resistant; 2intensive care unit.
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identified in four isolates from four different patients; each one from a
different ICU. All of these clones were different from the first VRE
clones detected eight years ago in our hospital.
DISCUSSION
Glycopeptide resistance is disseminated among E. faecium isolates
around the world14. However, to date the first reported VRE outbreaks
were attributed to E. faecalis1,3,8,12,13,22, while occurrence of vancomycin-
resistant E. faecium has been sporadic10,25. On the other hand, the first
VRE isolated in Brazil was an E. faecium strain with the vanD2
phenotype recovered from a patient with sepsis in Curitiba. This fact
drew attention for a potential problem that might be coming along in
our healthcare institutions thereafter10. In the following years, no
additional cases of VRE were detected in Curitiba, although several
cases of VRE identified as either E. faecium or E. faecalis harboring
VanA phenotype were documented in São Paulo25,26.
VRE became increasingly problematic for institutions in which
they now are endemic. Controlling the VRE spreading may become a
less difficult and costly task if the epidemiology is better understood21.
In these settings, colonized and infected patients and colonized
environmental surfaces may serve as persistent reservoirs. The
molecular epidemiology of VRE in a setting where it is endemic is
more complex. Several patterns of VRE transmission in non-outbreak
periods have been reported (eg. polyclonal, oligoclonal,
monoclonal)2,5,17,20,21,24. Molecular-typing techniques can be important
tools for efficiently identifying clonal VRE dissemination. The
heterogeneity of nosocomial VRE in centers in which this organism is
endemic likely reflects antimicrobial selective pressure at work in high-
risk patient populations combined with the constant introduction of
new strains by patients transferred from other institutions21.
In our institution, eight years apart from its introduction,
vancomycin-resistant E. faecalis has remained apparently oligoclonal
in the ICUs. On the other hand, we have noted a regular appearance of
E. faecium over the last years with its worse resistance profile. The
widespread dissemination of these two species likely reflects the
transfer of patients with undetected colonization between hospital
wards. However, the reasons for the maintenance of this oligoclonal
pattern in our institution are unclear. Vancomycin-resistant E. faecalis
incidence has been maintained high but stable in the last three years in
our setting. Thus, the infection control measures must be reinforced in
order to reduce these high incidence rates.
All vancomycin-resistant E. faecalis clones identified in this study
were distinct from the first one previously isolated in HSP. In addition,
the major vancomycin-resistant E. faecalis clone isolated in our setting
is similar to those previously isolated in Porto Alegre and Rio de Janeiro
in 200122. The predominant clone, denominated “B” has high-level of
resistance to gentamicin and was isolated from three ICUs. This fact
may suggest an inter-hospital dissemination of this clone among
Brazilian states.
Faster VRE detection methods may control the nosocomial spread
of this pathogen among new patients that may become index cases for
dissemination21. In our study we used the PCR method, which provide
results in less than 48 hours and proved to be an excellent method to
identify this microorganism.
In conclusion, the present study demonstrated that the initial VRE
clones (mainly E. faecalis) were replaced by new ones, eight years
apart from its first isolation in our hospital. Certainly, the spread of a
single clone via patient-to-patient transmission through healthcare
professional hands represents the major concern for infection control
team. Probably, VRE will continue to be a significant nosocomial
pathogen and continuous efforts aimed to understanding their molecular
epidemiology are warranted.
RESUMO
Caracterização molecular de espécies de Enterococci resistentes
à vancomicina oito anos após seu primeiro isolamento
em São Paulo, Brasil
E. faecium contendo o gene vanA foi a primeira espécie de VRE
descrita, no Brasil. Apesar disto, E. faecalis resistente a vancomicina
Fig. 1 - PFGE profiles of SmaI-digested chromosomal DNA of vancomycin-resistant E.
faecalis isolates obtained from colonized inpatients from Hospital São Paulo, Brazil. Lanes
l, molecular size markers (48.5kb). lane 1: clone “A”; lane 2: clone “A”; lanes 3-8: clone
“B”; lane 9: clone “C”.
Fig. 2 - PFGE profiles of SmaI-digested chromosomal DNA of vancomycin-resistant E.
faecium isolates obtained from patients from Hospital São Paulo, Brazil. l: lambda ladder
(48.5 kb); lane 1: clone “A”; lane 2: clone “B”; lane 3: clone “C1”; lane 4: clone “D”; lane 5:
clone “C2”; lane 6: clone “B”; lane 7: clone “B”; lane 8: clone “B”; lane 9: clone “E”; lane
10: clone “F”.
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tem se tornado a espécie predominante nos hospitais brasileiros.O
objetivo desse estudo foi avaliar a relação genética de VREs isolados
em um hospital de ensino brasileiro após oito anos de seu primeiro
isolamento. Analisamos 37 isolados de VRE obtidos de 81 culturas de
vigilância de pacientes admitidos nas quatro maiores Unidades de
Tratamento Intensivo em Fevereiro de 2006. A presença do gene vanA
foi analisada por PCR e a caracterização molecular por PFGE. Todas
as amostras VRE carreavam o gene vanA. Entre os E. faecalis
vancomicina-resistentes, dois distintos grupos clonais foram
observados. E. faecium resistente a vancomicina pertencentes a cinco
clones distintos foram demonstrados por tipagem molecular. Todos
esses clones foram diferentes do primeiro clone de enterococo resistente
a vancomicina isolado oito anos atrás em nosso hospital.
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